Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H47NO2 |
| Molecular Weight | 405.6569 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC\C(=N/O)[C@](C)(CCCO)[C@H]3CC[C@]12C
InChI
InChIKey=OBKBVSFXEIFOMS-YVABUZGXSA-N
InChI=1S/C26H47NO2/c1-18(2)8-6-9-19(3)21-11-12-22-20-10-13-24(27-29)26(5,15-7-17-28)23(20)14-16-25(21,22)4/h18-23,28-29H,6-17H2,1-5H3/b27-24+/t19-,20+,21-,22+,23+,25-,26-/m1/s1
| Molecular Formula | C26H47NO2 |
| Molecular Weight | 405.6569 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:31:02 GMT 2025
by
admin
on
Tue Apr 01 16:31:02 GMT 2025
|
| Record UNII |
3W389841RN
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
949080-24-4
Created by
admin on Tue Apr 01 16:31:02 GMT 2025 , Edited by admin on Tue Apr 01 16:31:02 GMT 2025
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
3W389841RN
Created by
admin on Tue Apr 01 16:31:02 GMT 2025 , Edited by admin on Tue Apr 01 16:31:02 GMT 2025
|
PRIMARY | |||
|
300000041473
Created by
admin on Tue Apr 01 16:31:02 GMT 2025 , Edited by admin on Tue Apr 01 16:31:02 GMT 2025
|
PRIMARY | |||
|
14291-24-8
Created by
admin on Tue Apr 01 16:31:02 GMT 2025 , Edited by admin on Tue Apr 01 16:31:02 GMT 2025
|
PRIMARY | |||
|
117902620
Created by
admin on Tue Apr 01 16:31:02 GMT 2025 , Edited by admin on Tue Apr 01 16:31:02 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Target: Peripheral-type benzodiazepine receptor
|
||
|
ACTIVE MOIETY |
A first set of in vitro studies showed that TRO40303 (from 0.3 to 3 .MU.mol/L) protected HepG2 cells and primary mouse embryonic hepatocytes (PMEH) from palmitate intoxication, a model mimicking steatohepatitis. Further studies were then preformed in a mouse model of Fas-induced fulminant hepatitis induced by injecting Jo2 anti-Fas antibody. When mice received a sublethal dose of Jo2 at 125 .MU.g/kg, TRO40303 pretreatment prevented liver enzyme elevation in plasma in parallel with a decrease in cytochrome C release from mitochondria and caspase 3 and 7 activation in hepatic tissue. When higher, lethal doses of Jo2 were administered, TRO40303 (10 and 30 mg/kg) significantly reduced mortality by 6590% when administered intraperitoneally (i.p.) 1 h before Jo2 injection, a time when TRO40303 plasma concentrations reached their peak. TRO40303 (30 mg/kg, i.p.) was also able to reduce mortality by 3050% when administered 1 h postlethal Jo2 intoxication. These results suggest that TRO40303 could be a promising new therapy for the treatment or prevention of hepatitis.
|